Toronto Western Hospital

BlueRock's Phase I study with bemdaneprocel in patients with Parkinson's disease meets primary endpoint

Retrieved on: 
Monday, September 18, 2023

Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.

Key Points: 
  • Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.
  • The data was recently presented at the International Congress of Parkinson's Disease and Movement Disorders in Copenhagen, Denmark.
  • There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case.
  • Based on these results, planning is underway for a Phase II study that is expected to begin enrolling patients in H1 (first half) 2024.

18th Grand Cru Culinary Wine Festival raises more than $59 million for University Health Network

Retrieved on: 
Tuesday, November 1, 2022

The 'Grand Cru' of fundraising: 18 years and $127 million

Key Points: 
  • The 'Grand Cru' of fundraising: 18 years and $127 million
    An eclectic and delicious three-day weekend full of festivities, Grand Cru Culinary Wine Festival is the largest event of its kind.
  • The spectacular Grand Cru Live Auction featured during the tasting, raised more than $1.3 million.
  • "The Grand Cru Culinary Wine Festival has featured the future of Canadian health care on its exclusive menu since 2005, raising more than $127 million.
  • Part of University Health Network (UHN), UHN Foundation raises funds for research, education and the enhancement of patient care at Toronto General and Toronto Western hospitals, Toronto Rehab and The Michener Institute of Education at UHN.

VCIB and 7Gen partner to lead the charge in EV fleet adoption

Retrieved on: 
Thursday, July 28, 2022

VCIB has provided 7Gen with a $3.2 million loan to support the purchase and lease of ten EV trucks and the required EV fast chargers to accelerate the delivery of EV fleets in Canada.

Key Points: 
  • VCIB has provided 7Gen with a $3.2 million loan to support the purchase and lease of ten EV trucks and the required EV fast chargers to accelerate the delivery of EV fleets in Canada.
  • This EV fleet is estimated to reduce CO2 emissions by 4,140 tonnes over the trucks seven-year lease period.
  • The partnership between VCIB and 7Gen showcases a new way of business that facilitates the EV fleet transition a business model made possible thanks to project developers such as 7Gen that offer an end-to-end fleet electrification package.
  • It provides turnkey EV-as-a-service fleet electrification execution support, financing, and software for fleet managers, marine terminals and airports that want to join the EV revolution.

SpinaFX Medical Announces Dr. Kieran Murphy as Chief Medical Officer

Retrieved on: 
Tuesday, April 5, 2022

TORONTO, April 5, 2022 /PRNewswire/ - Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX), is pleased to announce the appointment of Dr. Kieran Murphy as Chief Medical Officer and member of the Board of Directors of SpinaFX Medical.

Key Points: 
  • TORONTO, April 5, 2022 /PRNewswire/ - Minimally invasive image-guided therapy start-up, SpinaFX Medical Inc. (SpinaFX), is pleased to announce the appointment of Dr. Kieran Murphy as Chief Medical Officer and member of the Board of Directors of SpinaFX Medical.
  • "Dr. Murphy has been a pioneer in the field of intradiscal ozone for the treatment of herniated lumbar discs since 2004," said SpinaFX Medical CEO Jeff Cambra.
  • He has also created and led medical education programs in Ireland, the United States, the Middle East and elsewhere.
  • Headquartered in Ontario, Canada, SpinaFX is a medical device company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to herniated discs.

DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application

Retrieved on: 
Tuesday, November 30, 2021

The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.

Key Points: 
  • The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX) and its subsidiary, PentixaPharm GmbH, are working with CanProbe and UHN to provide PENTIXAFOR to patients in Toronto.
  • The intent is to provide further support toward the approval of PENTIXAFOR as a diagnostic agent for a portfolio of different indications.
  • "We are delighted to see this partnership emerging between PentixaPharm, CanProbe, and UHN", adds Luke Brzozowski, Senior Director, Techna and Diagnostics Innovation, University Health Network.

Canada Infrastructure Bank Invests $19.3 million in Toronto Western Hospital Retrofit Project

Retrieved on: 
Thursday, October 21, 2021

TORONTO, Oct. 21, 2021 /CNW/ - The Canada Infrastructure Bank (CIB) has reached financial close on the world's largest raw wastewater energy transfer project, located at Toronto Western Hospital, part of the University Health Network (UHN).

Key Points: 
  • TORONTO, Oct. 21, 2021 /CNW/ - The Canada Infrastructure Bank (CIB) has reached financial close on the world's largest raw wastewater energy transfer project, located at Toronto Western Hospital, part of the University Health Network (UHN).
  • Under the terms of the agreement, the CIB will invest up to $19.3 million in subordinated debt and Vancity Community Investment Bank will invest $15.3 million in senior debt.
  • The Government of Canada is providing a grant under the Environment and Climate Change Canada - Low Carbon Economy Fund.
  • This milestone would not have been possible without the support of the University Health Network and the City of Toronto and our project partners, Enbridge Gas, the Canada Infrastructure Bank and VanCity Community Investment Bank.

ARTMS Inc. Announces Health Canada Submission for Ga-68 Production and Tri-party Collaboration to Advance Ga-68 Imaging Products

Retrieved on: 
Thursday, October 14, 2021

ARTMS Health Canada filing will help alleviate the current supply constraints and provide innovators the ability to advance new radiopharmaceutical drugs into development.

Key Points: 
  • ARTMS Health Canada filing will help alleviate the current supply constraints and provide innovators the ability to advance new radiopharmaceutical drugs into development.
  • The Ga-68 regulatory filing in Canada is the next step in ARTMS goal to prevent the significant supply issues of this important medical isotope.
  • Any interruptions to the supply chain will negatively impact patients and drug innovators, explained Charles S. Conroy, Chief Executive Officer of ARTMS.
  • We believe ARTMS solid target approach to Ga-68 production will play a key role in increasing the availability of this important isotope.